Identification/NN
of/IN
Polymorphisms/NNS
in/IN
CYP2E1/NN
Gene/NN
and/CC
Association/NN
Analysis/NN
among/IN
Chronic/JJ
HBV/NN
Patients/NNS
./.
====================
Cytochrome/DT
P450/NN
2E1/NN
(/(
CYP2E1/NN
)/)
is/VBZ
a/DT
member/NN
of/IN
the/DT
cytochrome/NN
P450/NN
superfamily/RB
,/,
and/CC
it/PRP
is/VBZ
a/DT
key/JJ
enzyme/NN
responsible/JJ
for/IN
the/DT
metabolic/JJ
activation/NN
of/IN
many/JJ
small/JJ
molecular-weight/NN
compounds/NNS
such/JJ
as/IN
alcohol/NN
,/,
which/WDT
is/VBZ
classified/VBN
as/IN
a/DT
human/JJ
carcinogen/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
identified/VBD
19/CD
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
in/IN
CYP2E1/NN
in/IN
Korean/JJ
population/NN
./.
====================
In/IN
these/DT
SNPs/NNS
,/,
we/PRP
examined/VBD
possible/JJ
genetic/JJ
association/NN
of/IN
CYP2E1/NN
polymorphisms/NNS
with/IN
HBV/NN
clearance/NN
and/CC
the/DT
risk/NN
of/IN
hepatocellular/JJ
carcinoma/NN
(/(
HCC/NN
)/)
./.
====================
Five/CD
common/JJ
polymorphic/JJ
sites/NNS
were/VBD
selected/VBN
,/,
CYP2E1/NN
polymorphisms/NNS
at/IN
rs3813867/NN
,/,
rs3813870/NN
,/,
rs2070673/NN
,/,
rs2515641/NN
and/CC
rs2480257/NN
,/,
considering/VBG
their/PRP$
allele/NN
frequencies/NNS
,/,
haplotypetagging/VBG
status/NN
and/CC
LDs/NNS
for/IN
genotyping/VBG
in/IN
largerscale/JJ
subjects/NNS
(/(
n=1,092/CD
)/)
./.
====================
Statistical/JJ
analysis/NN
demonstrated/VBD
that/IN
CYP2E1/NN
polymorphisms/NNS
and/CC
haplotypes/NNS
show/VBP
no/DT
significant/JJ
association/NN
with/IN
HBV/NN
clearance/NN
,/,
HCC/NN
occurrence/NN
and/CC
onset/NN
age/NN
of/IN
HCC/NN
(/(
p＞0.05/NN
)/)
./.
====================
Previous/JJ
studies/NNS
,/,
however/RB
,/,
have/VBP
shown/VBN
contradictory/JJ
findings/NNS
on/IN
associations/NNS
of/IN
CYP2E1/NN
polymorphisms/NNS
with/IN
CYP2E1/NN
activities/NNS
and/CC
HCC/NN
risk/NN
./.
====================
Comparing/VBG
the/DT
contrasting/VBG
results/NNS
of/IN
previous/JJ
researches/NNS
suggest/VBP
that/IN
CYP2E1/NN
polymorphism/NN
is/VBZ
associated/VBN
with/IN
CYP2E1/NN
activity/NN
induced/VBN
by/IN
ethanol/NN
,/,
but/CC
is/VBZ
not/RB
directly/RB
associated/VBN
with/IN
HCC/NN
risk/NN
./.
====================
CYP2E1/NN
variation/haploype/NN
information/NN
identified/VBD
in/IN
this/DT
study/NN
will/MD
provide/VB
valuable/JJ
information/NN
for/IN
future/JJ
studies/NNS
on/IN
CYP2E1/NN
./.
====================
The/DT
infection/NN
of/IN
hepatitis/NN
virus/NN
B/NN
(/(
HBV/NN
)/)
is/VBZ
considered/VBN
as/IN
an/DT
important/JJ
health/NN
problem/NN
worldwide/NN
with/IN
an/DT
estimation/NN
of/IN
350/CD
million/NN
people/JJ
chronically/RB
infected/JJ
with/IN
the/DT
disease/NN
(/(
Lavanchy/NN
,/,
2005/CD
)/)
./.
====================
Although/IN
hepatic/JJ
complications/NNS
do/VBP
not/RB
develop/VB
in/IN
most/JJS
chronic/JJ
hepatitis/NN
B/NN
carriers/NNS
,/,
15/CD
%/NN
to/TO
40/CD
%/NN
will/MD
develop/VB
liver/NN
cirrhosis/NN
(/(
LC/NN
)/)
and/CC
hepatocellular/JJ
carcinoma/NN
(/(
HCC/NN
)/)
,/,
which/WDT
come/VBP
with/IN
serious/JJ
sequelae/NN
during/IN
their/PRP$
lifetime/JJ
(/(
Bosch/NNP
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
Continuous/JJ
consumption/NN
of/IN
more/RBR
than/IN
80g/DT
of/IN
ethanol/NN
everyday/RB
for/IN
a/DT
period/NN
longer/RBR
than/IN
10/CD
years/NNS
increases/VBZ
the/DT
risk/NN
of/IN
HCC/NN
by/IN
approximately/RB
fivefold/RB
;/:
however/RB
,/,
consumption/NN
of/IN
less/RBR
than/IN
80g/DT
of/IN
alcohol/NN
per/IN
day/NN
does/VBZ
not/RB
significantly/RB
increases/VBZ
the/DT
risk/NN
of/IN
HCC/NN
(/(
Morgan/NNP
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
Although/IN
the/DT
development/NN
of/IN
alcohol/NN
related/JJ
to/TO
HCC/NN
involves/VBZ
several/JJ
factors/NNS
including/VBG
the/DT
presence/NN
of/IN
cirrhosis/NN
,/,
oxidative/JJ
stress/NN
,/,
disturbed/JJ
DNA/NN
methylation/NN
,/,
and/CC
defective/JJ
retinoic/JJ
acid/NN
signaling/NN
,/,
the/DT
precise/JJ
mechanisms/NNS
on/IN
how/WRB
alcohol/NN
causes/VBZ
HCC/NN
at/IN
a/DT
molecular/JJ
level/NN
are/VBP
just/RB
beginning/VBG
to/TO
emerge/VB
(/(
Seitz/NNP
&/CC
Stickel/NN
2007/CD
;/:
Stickel/NNP
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
According/VBG
to/TO
the/DT
International/JJ
Agency/NN
for/IN
Research/NN
on/IN
Cancer/NN
,/,
ethanol/NN
is/VBZ
classified/VBN
as/IN
a/DT
human/JJ
carcinogen/NN
because/IN
it/PRP
induces/VBZ
HCC/NN
in/IN
animals/NNS
and/CC
increases/VBZ
the/DT
risk/NN
for/IN
developing/VBG
HCC/NN
in/IN
humans/NNS
(/(
Baan/NNP
et/FW
al./FW
,/,
2007/CD
;/:
Seitz/NNP
and/CC
Stickel/NN
2007/CD
)/)
./.
====================
Cytochrome/DT
P450/NN
2E1/NN
(/(
CYP2E1/NN
)/)
,/,
a/DT
member/NN
of/IN
the/DT
cytochrome/NN
P450/NN
superfamily/RB
is/VBZ
important/JJ
for/IN
the/DT
metabolic/JJ
activation/NN
of/IN
many/JJ
lowmolecularweight/JJ
toxicants/NNS
such/JJ
as/IN
Nnitrosamines/NNS
,/,
aniline/NN
,/,
vinyl/JJ
chloride/NN
,/,
urethane/NN
and/CC
alcohol/NN
(/(
Guengerich/JJ
et/FW
al./FW
,/,
1991/CD
)/)
./.
====================
The/DT
participation/NN
of/IN
CYP2E1/NN
in/IN
the/DT
ethanol/NN
metabolizing/VBG
process/NN
is/VBZ
less/RBR
important/JJ
than/IN
alcohol/NN
dehydrogenase/NN
(/(
ADH/NN
)/)
and/CC
aldehyde/NN
dehydrogenase/NN
(/(
ALDH/NN
)/)
./.
====================
However/RB
,/,
continuous/JJ
ethanol/NN
consumption/NN
is/VBZ
known/VBN
to/TO
increase/VB
the/DT
activity/NN
of/IN
CYP2E1/NN
up/IN
to/TO
20/CD
fold/JJ
,/,
a/DT
major/JJ
constituent/NN
of/IN
the/DT
microsomal/JJ
ethanol/NN
oxidizing/VBG
system/NN
in/IN
the/DT
liver/NN
(/(
Stickel/NN
&/CC
Osterreicher/RBR
2006/CD
;/:
Takahashi/NNP
et/FW
al./FW
,/,
1993/CD
)/)
./.
====================
Therefore/RB
,/,
alcohol/NN
’/NN
s/NNS
metabolizing/VBG
capacity/NN
is/VBZ
increased/VBN
in/IN
heavy/JJ
drinkers/VBZ
./.
====================
Moreover/RB
,/,
CYP2E1/NN
often/RB
catalyze/VBP
the/DT
metabolic/JJ
activation/NN
of/IN
various/JJ
procarcinogens/NNS
to/TO
eventual/JJ
carcinogens/NNS
(/(
Guengerich/JJ
et/FW
al./FW
,/,
1991/CD
;/:
Koop/NN
,/,
1992/CD
)/)
./.
====================
Genetic/JJ
variation/NN
appears/VBZ
to/TO
contribute/VB
to/TO
interindividual/JJ
variation/NN
in/IN
CYP2E1/NN
expression/NN
levels/NNS
and/CC
activities/NNS
(/(
McCarver/NN
et/FW
al./FW
,/,
1998/CD
)/)
./.
====================
Specifically/RB
,/,
RsaI/NN
polymorphism/NN
(/(
CYP2E1*5B/NN
)/)
(/(
rs2031920/CD
)/)
has/VBZ
been/VBN
associated/VBN
with/IN
decreased/VBN
CYP2E1/NN
activity/NN
or/CC
inducibility/NN
(/(
Hayashi/NNP
et/FW
al./FW
,/,
1991/CD
;/:
Lucas/NNP
et/FW
al./FW
,/,
1995/CD
;/:
Marchand/NNP
et/FW
al./FW
,/,
1999/CD
;/:
Watanabe/NNP
et/FW
al./FW
,/,
1994/CD
)/)
./.
====================
Functional/JJ
CYP2E1/NN
polymorphisms/NNS
might/MD
therefore/RB
influence/VBP
on/IN
susceptibility/NN
to/TO
cancer/NN
development/NN
./.
====================
In/IN
one/CD
study/NN
,/,
common/JJ
genotypes/NNS
were/VBD
associated/VBN
with/IN
risk/NN
of/IN
HCC/NN
(/(
Yu/NNP
et/FW
al./FW
,/,
1995/CD
)/)
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
increased/VBD
risk/NN
of/IN
HCC/NN
was/VBD
observed/VBN
with/IN
the/DT
rare/JJ
genotype/NN
carriers/NNS
in/IN
another/DT
study/NN
(/(
Ladero/NN
et/FW
al./FW
,/,
1996/CD
)/)
./.
====================
These/DT
studies/NNS
suggest/VBP
that/IN
variation/NN
of/IN
CYP2E1/NN
can/MD
influence/VB
individual/JJ
’/NN
s/NNS
risk/NN
of/IN
HCC/NN
./.
====================
Based/VBN
on/IN
these/DT
studies/NNS
,/,
we/PRP
have/VBP
formed/VBN
a/DT
hypothesis/NN
that/IN
polymorphisms/NNS
of/IN
CYP2E1/NN
can/MD
affect/VB
HCC/NN
progression/NN
among/IN
HBV-infected/JJ
patients/NNS
and/CC
therefore/RB
performed/VBN
a/DT
screening/NN
of/IN
CYP2E1/NN
to/TO
examine/VB
its/PRP$
genetic/JJ
association/NN
with/IN
HBV/NN
clearance/NN
and/CC
HCC/NN
progression/NN
./.
====================
A/DT
total/JJ
number/NN
of/IN
1,092/NN
Korean/JJ
subjects/NNS
having/VBG
either/CC
present/JJ
or/CC
past/JJ
evidence/NN
of/IN
HBV/NN
infection/NN
were/VBD
prospectively/RB
enrolled/JJ
from/IN
the/DT
outpatient/JJ
clinic/JJ
of/IN
the/DT
liver/NN
unit/NN
or/CC
from/IN
the/DT
Center/JJ
for/IN
Health/NN
Promotion/NN
of/IN
Seoul/JJ
National/JJ
University/NN
Hospital/JJ
from/IN
January/NN
2001/CD
to/TO
August/JJ
2003/CD
./.
====================
All/DT
the/DT
study/NN
subjects/NNS
were/VBD
of/IN
Korean/JJ
ethnicity/NN
./.
====================
Subjects/NNS
were/VBD
classified/VBN
into/IN
two/CD
different/JJ
groups/NNS
:/:
CC/NN
(/(
chronic/JJ
carrier/NN
)/)
and/CC
SR/JJ
(/(
spontaneously/RB
recovered/VBD
)/)
,/,
according/VBG
to/TO
serological/JJ
markers/NNS
./.
====================
The/DT
CC/NN
and/CC
SR/JJ
cohorts/NNS
consisted/VBD
of/IN
658/CD
and/CC
434/CD
subjects/NNS
,/,
respectively/RB
,/,
and/CC
the/DT
CC/NN
cohort/NN
was/VBD
composed/VBN
of/IN
338/CD
CH/LC/NN
and/CC
320/CD
HCC/NN
patients/NNS
(/(
Table/JJ
1/CD
)/)
./.
====================
The/DT
diagnoses/NNS
of/IN
the/DT
CC/NN
and/CC
SR/JJ
subjects/NNS
were/VBD
established/VBN
by/IN
repeated/VBN
seropositivity/NN
for/IN
the/DT
hepatitis/NN
B/NN
surface/NN
antigen/NN
(/(
HBsAg/NN
)/)
(/(
EnzygnostⓇ/NNP
HBsAg/NN
5.0/CD
;/:
Dade/NNP
Behring/VBG
,/,
Marburg/NNP
,/,
Germany/NNP
)/)
over/IN
a/DT
six-month/JJ
period/NN
,/,
and/CC
for/IN
both/DT
anti-HBs/JJ
(/(
EnzygnostⓇ/NNP
Anti-HBs/JJ
II/CD
;/:
Dade/NNP
Behring/VBG
,/,
Marburg/NNP
,/,
Germany/NNP
)/)
and/CC
anti-HBc/JJ
(/(
AB-Corek/NNP
;/:
DiaSorin/NN
s./CC
r./NNP
l./FW
,/,
Saluggia/NNP
,/,
Italy/RB
)/)
of/IN
the/DT
IgG/NN
type/NN
without/IN
HBsAg/NN
,/,
respectively/RB
./.
====================
We/PRP
excluded/VBD
subjects/NNS
that/DT
were/VBD
positive/JJ
only/RB
for/IN
antiHBs/JJ
and/CC
not/RB
for/IN
antiHBc/JJ
,/,
and/CC
those/DT
positive/JJ
for/IN
antiHCV/JJ
or/CC
antiHIV/JJ
(/(
GENEDIAⓇ/NNP
;/:
Greencross/NNP
Life/NN
Science/NNP
Corp./NNP
,/,
Yonginshi/NNP
,/,
Korea/NN
,/,
HCVⓇ3.2/NN
;/:
DongA/NNP
Pharmaceutical/JJ
Co./NNP
,/,
Seoul/JJ
,/,
Korea/NN
)/)
./.
====================
Subjects/NNS
whose/WP$
average/JJ
alcohol/NN
consumption/NN
assessed/VBN
by/IN
interview/NN
was/VBD
＞510/CD
g/day/NN
or/CC
average/JJ
cigarette/NN
smoking/NN
was/VBD
＞1/CD
pack/day/NN
were/VBD
excluded/VBN
./.
====================
Patients/NNS
who/WP
had/VBD
any/DT
other/JJ
types/NNS
of/IN
liver/NN
diseases/NNS
such/JJ
as/IN
autoimmune/JJ
hepatitis/NN
,/,
toxic/JJ
hepatitis/NN
,/,
biliary/JJ
cirrhosis/NN
and/CC
BuddChiari/NNP
syndrome/NN
were/VBD
also/RB
excluded/VBN
./.
====================
No/DT
patients/NNS
in/IN
our/PRP$
study/NN
had/VBD
a/DT
previous/JJ
history/JJ
of/IN
immunosuppression/NN
or/CC
antiviral/JJ
treatment/NN
./.
====================
Informed/VBN
consent/JJ
was/VBD
obtained/VBN
from/IN
each/DT
patient/NN
,/,
and/CC
the/DT
Institutional/JJ
Review/NN
Board/JJ
of/IN
Human/JJ
Research/NN
at/IN
Seoul/JJ
National/JJ
University/NN
Hospital/JJ
approved/JJ
the/DT
study/NN
protocol/NN
./.
====================
All/DT
the/DT
patients/NNS
in/IN
the/DT
CC/NN
group/NN
had/VBD
been/VBN
on/IN
regular/JJ
medical/JJ
followup/JJ
and/CC
had/VBD
been/VBN
evaluated/VBN
with/IN
serum/NN
alphafetoprotein/NN
level/NN
assessment/NN
,/,
abdominal/JJ
ultrasonography/NN
,/,
and/or/CC
2phase/NN
spiral/JJ
liver/NN
CT/NN
scan/MD
more/RBR
than/IN
twice/RB
a/DT
year/NN
to/TO
detect/VB
early/JJ
stages/NNS
of/IN
HCC/NN
./.
====================
We/PRP
also/RB
performed/VBN
abdominal/JJ
MRI/NN
,/,
bone/NN
scan/NN
,/,
chest/VBP
CT/NN
,/,
brain/NN
MRI/NN
,/,
brain/NN
CT/NN
,/,
hepatic/JJ
angiography/NN
or/CC
PET/NN
scan/NN
in/IN
some/DT
patients/NNS
according/VBG
to/TO
the/DT
clinical/JJ
decisions/NNS
./.
====================
Liver/RB
cirrhosis/NN
was/VBD
diagnosed/VBN
pathologically/RB
or/CC
by/IN
the/DT
clinical/JJ
evidences/NNS
of/IN
portal/JJ
hypertension/NN
such/JJ
as/IN
visible/JJ
collateral/JJ
vessels/NNS
on/IN
the/DT
abdominal/JJ
wall/NN
,/,
esophageal/JJ
varices/VBZ
on/IN
esophagogastroscopy/NN
,/,
palpable/JJ
splenomegaly/RB
and/CC
sonographically/RB
definite/JJ
findings/NNS
of/IN
cirrhotic/JJ
liver/NN
or/CC
ascites/VBZ
./.
====================
HCC/NN
was/VBD
diagnosed/VBN
as/IN
described/VBN
previously/RB
(/(
the/DT
age/NN
of/IN
onset/NN
was/VBD
determined/VBN
by/IN
the/DT
date/NN
of/IN
the/DT
diagnosis/NN
./.
)/)
====================
(/(
Bruix/NN
et/FW
al./FW
,/,
2001/CD
)/)
./.
====================
We/PRP
have/VBP
sequenced/VBN
exons/NNS
,/,
including/VBG
exonintron/NN
boundaries/NNS
and/CC
their/PRP$
flanking/JJ
regions/NNS
,/,
including/VBG
the/DT
promoter/NN
region/NN
(/(
1.5/CD
kb/NN
)/)
to/TO
discover/RB
polymorphisms/NNS
in/IN
24/CD
Korean/NN
unregulated/JJ
individual/JJ
DNA/NN
samples/NNS
using/VBG
the/DT
ABI/NN
PRISM/NN
3700/CD
DNA/NN
analyzer/NN
(/(
Applied/VBN
Biosystems/NNS
,/,
Foster/NN
City/NN
,/,
CA/NNP
)/)
./.
====================
Primer/NN
sets/NNS
for/IN
the/DT
amplification/NN
and/CC
sequencing/NN
analysis/NN
of/IN
CYP2E1/NN
were/VBD
designed/VBN
based/VBN
on/IN
GenBank/NN
sequences/NNS
(/(
Ref/NN
./.
====================
Genome/NN
seq/NN
./.
====================
;/:
NT_008818.16/CD
)/)
./.
====================
Sequence/NN
variants/NNS
were/VBD
verified/VBN
by/IN
chromatograms/NNS
./.
====================
For/IN
genotyping/VBG
of/IN
polymorphic/JJ
sites/NNS
in/IN
our/PRP$
HBV/NN
study/NN
,/,
amplifying/VBG
primers/NNS
and/CC
probes/NNS
were/VBD
designed/VBN
for/IN
TaqMan/NN
(/(
Livak/JJ
,/,
1999/CD
)/)
./.
====================
One/CD
allelic/JJ
probe/NN
was/VBD
labeled/VBN
with/IN
the/DT
FAM/NN
dye/NN
and/CC
the/DT
other/JJ
with/IN
the/DT
fluorescent/JJ
VIC/NN
dye/NN
for/IN
TaqMan/NN
probes/NNS
./.
====================
Information/NN
regarding/VBG
the/DT
primers/NNS
is/VBZ
attached/VBN
in/IN
Table/JJ
2/CD
./.
====================
Primer/NN
Express/NN
(/(
Applied/VBN
Biosystems/NNS
,/,
Foster/NN
City/NN
,/,
CA/NN
)/)
was/VBD
used/VBN
to/TO
design/VB
the/DT
MGB/NN
TaqMan/NN
probes/NNS
./.
====================
PCRs/NNS
were/VBD
run/JJ
in/IN
a/DT
TaqMan/JJ
Universal/JJ
Master/NN
Mix/NN
without/IN
UNG/NN
(/(
Applied/VBN
Biosystems/NNS
)/)
,/,
with/IN
PCR/NN
primer/NN
concentrations/NNS
of/IN
900/CD
nM/NN
and/CC
TaqMan/NN
MGB-probe/NN
concentrations/NNS
of/IN
200/CD
nM/NN
./.
====================
Reactions/NNS
were/VBD
performed/VBN
in/IN
a/DT
384-well/JJ
format/IN
in/IN
a/DT
total/JJ
reaction/NN
volume/NN
of/IN
5/CD
ml/NN
using/VBG
20/CD
ng/NN
of/IN
genomic/JJ
DNA/NN
./.
====================
The/DT
plates/NNS
were/VBD
then/RB
placed/VBN
in/IN
a/DT
thermal/JJ
cycler/NN
(/(
PE/NN
9700/CD
,/,
Applied/VBN
Biosystems/NNS
)/)
and/CC
heated/JJ
at/IN
50oC/JJ
for/IN
2/CD
min/NN
and/CC
95oC/JJ
for/IN
10/CD
min/NN
,/,
followed/VBN
by/IN
40/CD
cycles/NNS
of/IN
95oC/JJ
for/IN
15/CD
s/NNS
and/CC
60oC/JJ
for/IN
1/CD
min/NN
with/IN
a/DT
final/JJ
soak/NN
at/IN
25oC/NN
./.
====================
The/DT
TaqMan/NN
assay/NN
plates/VBZ
were/VBD
transferred/VBN
to/TO
the/DT
Prism/NN
7900HT/CD
instrument/JJ
(/(
Applied/VBN
Biosystems/NNS
)/)
where/WRB
the/DT
fluorescence/NN
intensity/NN
in/IN
each/DT
well/RB
of/IN
the/DT
plate/NN
was/VBD
read/VBN
./.
====================
Fluorescence/NN
data/NNS
files/NNS
from/IN
each/DT
plate/NN
were/VBD
analyzed/VBN
by/IN
automated/JJ
allelecalling/VBG
software/JJ
(/(
SDS/NN
2.1/CD
)/)
./.
====================
We/PRP
searched/VBD
for/IN
a/DT
spine/NN
of/IN
strong/JJ
|D/NN
’/CD
|/CD
and/CC
LD/NN
coefficient/JJ
r2/NN
between/IN
all/DT
pairs/NNS
of/IN
biallelic/JJ
loci/NNS
(/(
Hedrick/JJ
&/CC
Kumar/JJ
,/,
2001/CD
)/)
./.
====================
Linkage/JJ
disequilibrium/NN
(/(
LD/NN
)/)
was/VBD
inferred/VBN
using/VBG
the/DT
algorithm/NN
developed/VBD
by/IN
the/DT
Broad/JJ
Institute/JJ
(/(
using/VBG
the/DT
program/NN
Haploview/NN
)/)
(/(
Barrett/NN
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
Haplotypes/NNS
of/IN
each/DT
individual/JJ
were/VBD
inferred/VBN
using/VBG
the/DT
algorithm/NN
(/(
PHASE/NN
,/,
version/NN
2.0/CD
)/)
developed/VBD
by/IN
Stephens/NNS
et/FW
al/JJ
./.
====================
(/(
Stephens/NNS
et/FW
al./FW
,/,
2001/CD
)/)
./.
====================
Subjects/NNS
harboring/VBG
missing/VBG
genotypes/NNS
were/VBD
omitted/VBN
in/IN
the/DT
analysis/NN
of/IN
individual/JJ
singlenucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
and/CC
haplotypes/NNS
./.
====================
The/DT
genotyping/JJ
success/NN
rate/NN
was/VBD
＞99/CD
%/NN
,/,
so/RB
it/PRP
is/VBZ
unlikely/JJ
that/IN
omitting/VBG
a/DT
small/JJ
number/NN
of/IN
individuals/NNS
introduced/VBD
any/DT
bias/NNS
in/IN
the/DT
analysis/NN
./.
====================
For/IN
analysis/NN
of/IN
viral/JJ
clearance/NN
as/IN
an/DT
outcome/NN
,/,
logistic/JJ
regression/NN
models/NNS
were/VBD
used/VBN
for/IN
calculating/JJ
odds/NNS
ratios/NNS
(/(
95/CD
%/NN
confidential/JJ
interval/JJ
)/)
and/CC
corresponding/VBG
pvalues/NNS
controlling/VBG
for/IN
age/NN
(/(
continuous/JJ
value/NN
)/)
and/CC
sex/NN
(/(
male=0/NN
,/,
female=1/NN
)/)
as/IN
covariates/VBZ
./.
====================
HBV/NN
genotypes/NNS
,/,
HBV/NN
DNA/NN
and/CC
Alanine/NN
transaminase/NN
(/(
ALT/NN
)/)
levels/NNS
have/VBP
been/VBN
regarded/VBN
as/IN
important/JJ
factors/NNS
influencing/VBG
HBV/NN
clearance/NN
and/CC
the/DT
development/NN
of/IN
HCC/NN
./.
====================
However/RB
,/,
HBV/NN
genotype/NN
C/NN
is/VBZ
predominant/JJ
among/IN
CCs/NNS
of/IN
the/DT
virus/NN
in/IN
Korea/NN
(/(
Bae/NNP
et/FW
al./FW
,/,
2005/CD
;/:
Odgerel/NNP
et/FW
al./FW
,/,
2003/CD
;/:
Song/JJ
et/FW
al./FW
,/,
2005a/NN
;/:
Song/JJ
et/FW
al./FW
,/,
2005b/NN
;/:
Yoo/RB
et/FW
al./FW
,/,
2003/CD
)/)
,/,
and/CC
the/DT
HBV/NN
DNA/NN
and/CC
ALT/NN
levels/NNS
were/VBD
found/VBN
to/TO
be/VB
fluctuating/JJ
during/IN
the/DT
followup/JJ
for/IN
the/DT
majority/NN
of/IN
our/PRP$
HBV/NN
cohort/JJ
./.
====================
Therefore/RB
,/,
logistic/JJ
models/NNS
for/IN
HBV/NN
clearance/NN
were/VBD
adjusted/VBN
only/RB
for/IN
age/NN
and/CC
sex/NN
./.
====================
Statistical/JJ
power/JJR
is/VBZ
calculated/VBN
with/IN
PGA/NN
(/(
Power/JJR
for/IN
Genetic/JJ
Association/NN
Analyses/NNS
)/)
matlab/VBP
application/NN
(/(
http/NN
:/:
//dceg/JJ
./.
====================
cancer/NN
./.
====================
gov/bb/tools/pga/DT
)/)
(/(
Menashe/DT
et/FW
al./FW
,/,
2008/CD
)/)
./.
====================
PGA/NN
is/VBZ
an/DT
application/NN
specifically/RB
designed/VBN
to/TO
calculate/VB
statistical/JJ
power/JJR
and/CC
other/JJ
values/NNS
of/IN
casecontrol/JJ
genetic/JJ
association/NN
studies/NNS
./.
====================
For/IN
the/DT
present/JJ
study/NN
,/,
a/DT
codominant/JJ
(/(
1df/NN
)/)
model/NN
with/IN
relative/JJ
risk/NN
1.3/CD
,/,
disease/NN
prevalence/NN
value/NN
7.1/CD
%/NN
(/(
Lee/NNP
et/FW
al./FW
,/,
1998/CD
)/)
,/,
EDF/NN
(/(
Effective/JJ
Degree/NNP
of/IN
Freedom/JJ
)/)
2/CD
,/,
and/CC
alpha/NN
error/JJ
level/NN
5/CD
%/NN
were/VBD
used/VBN
to/TO
calculate/JJ
the/DT
statistical/JJ
power/JJR
of/IN
pvalues/NNS
for/IN
HBV/NN
clearance/NN
and/CC
HCC/NN
occurrence/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
examined/VBD
the/DT
association/NN
of/IN
CYP2E1/NN
polymorphisms/NNS
with/IN
persistent/JJ
HBV/NN
infection/NN
and/CC
HCC/NN
occurrence/NN
./.
====================
By/IN
direct/JJ
sequencing/NN
of/IN
24/CD
individuals/NNS
,/,
we/PRP
identified/VBD
19/CD
sequence/NN
variants/NNS
in/IN
the/DT
CYP2E1/NN
:/:
8/CD
in/IN
the/DT
promoter/NN
,/,
3/CD
in/IN
coding/VBG
regions/NNS
of/IN
exons/NNS
(/(
two/CD
nonsynon/JJ
ymous/JJ
and/CC
four/CD
synonymous/JJ
)/)
and/CC
8/CD
in/IN
introns/NNS
(/(
Fig/NN
./.
====================
1A/NN
,/,
Table/JJ
3/CD
)/)
./.
====================
We/PRP
analyzed/VBD
five/CD
polymorphisms/NNS
(/(
rs3813867/NN
,/,
rs3813870/NN
,/,
rs2070673/NN
,/,
rs2515641/NN
and/CC
rs2480257/NN
)/)
in/IN
CYP2E1/NN
./.
====================
These/DT
were/VBD
selected/VBN
for/IN
largerscale/JJ
genotyping/VBG
(/(
n=1,092/NN
)/)
by/IN
considering/VBG
their/PRP$
allele/NN
frequencies/NNS
,/,
haplotype-tagging/VBG
status/NN
,/,
and/CC
LDs/NNS
./.
====================
The/DT
minor/JJ
allele/NN
frequencies/NNS
of/IN
the/DT
SNPs/NNS
in/IN
Korean/JJ
population/NN
were/VBD
;/:
0.181/CD
(/(
rs3813867/NN
)/)
,/,
0.202/CD
(/(
rs3813870/NN
)/)
,/,
0.381/CD
(/(
rs2070673/NN
)/)
,/,
0.157/CD
(/(
rs2515641/NN
)/)
and/CC
0.392/CD
(/(
rs2480257/NN
)/)
(/(
Fig/NN
./.
====================
1A/NN
,/,
Table/JJ
3/CD
)/)
./.
====================
Genotype/NN
distributions/NNS
of/IN
all/DT
loci/NNS
were/VBD
in/IN
HardyWeinberg/JJ
equilibrium/NN
(/(
p＞0.05/NN
)/)
,/,
except/IN
for/IN
rs3813867/NN
(/(
p＜0.05/NN
,/,
Table/JJ
3/CD
)/)
./.
====================
Five/CD
SNPs/NNS
showed/VBD
low/JJ
LDs/NNS
(/(
Fig/NN
./.
====================
1C/NN
)/)
,/,
and/CC
four/CD
major/JJ
haplotypes/NNS
accounted/VBN
for/IN
over/IN
97.8/CD
%/NN
of/IN
the/DT
distribution/NN
(/(
Fig/NN
./.
====================
1B/NN
)/)
./.
====================
Association/NN
analyses/NNS
of/IN
HBV/NN
clearance/NN
(/(
HCC/LC/CH/NN
vs./CC
SR/JJ
)/)
and/CC
HCC/NN
occurrence/NN
(/(
HCC/NN
vs./CC
CH/LC/NN
)/)
for/IN
each/DT
polymorphism/NN
and/CC
haplotype/JJ
of/IN
the/DT
CYP2E1/NN
were/VBD
performed/VBN
using/VBG
logistic/JJ
regression/NN
models/NNS
(/(
Table/JJ
4/CD
)/)
,/,
controlling/VBG
age/NN
and/CC
sex/NN
as/IN
covariates/VBZ
(/(
gender/RB
and/CC
age/NN
were/VBD
significantly/RB
associated/VBN
with/IN
HBV/NN
clearance/NN
;/:
p＜0.05/NN
,/,
data/NNS
not/RB
shown/VBN
)/)
in/IN
our/PRP$
Korean/JJ
HBV/NN
study/NN
./.
====================
The/DT
statistical/JJ
powers/NNS
for/IN
each/DT
polymorphism/NN
are/VBP
also/RB
shown/VBN
in/IN
Table/JJ
4/CD
./.
====================
In/IN
the/DT
analysis/NN
,/,
CYP2E1/NN
polymorphisms/NNS
and/CC
haplotypes/NNS
did/VBD
not/RB
show/VB
significant/JJ
associations/NNS
with/IN
HBV/NN
clearance/NN
and/CC
the/DT
HCC/NN
occurrence/NN
(/(
p＞0.05/NN
,/,
Table/JJ
4/CD
)/)
./.
====================
The/DT
role/NN
of/IN
CYP2E1/NN
polymorphisms/NNS
in/IN
onset/NN
age/NN
of/IN
HCC/NN
was/VBD
also/RB
analyzed/VBD
using/VBG
Cox/NN
relative/JJ
hazards/VBZ
model/NN
among/IN
chronic/JJ
HBV/NN
patients/NNS
(/(
Table/JJ
4/CD
)/)
./.
====================
However/RB
,/,
no/DT
significant/JJ
genetic/JJ
effect/NN
was/VBD
observed/VBN
afterwards/IN
(/(
p＞0.05/NN
,/,
Table/JJ
4/CD
)/)
./.
====================
In/IN
the/DT
present/JJ
,/,
HCC/NN
is/VBZ
one/CD
of/IN
the/DT
most/JJS
common/JJ
tumors/NNS
among/IN
the/DT
prevalent/JJ
malignant/JJ
tumors/NNS
worldwide/NN
(/(
El/NN
Serag/NN
&/CC
Mason/NN
,/,
2000/CD
)/)
./.
====================
The/DT
increase/NN
in/IN
HCC/NN
occurrence/NN
is/VBZ
most/RBS
likely/RB
due/JJ
to/TO
the/DT
more/RBR
widespread/JJ
chronic/JJ
infection/NN
with/IN
HBV/NN
./.
====================
The/DT
virus-host/JJ
interactions/NNS
might/MD
influence/VB
different/JJ
disease/NN
outcomes/NNS
of/IN
HBV/NN
infections/NNS
(/(
Cruz/NN
et/FW
al./FW
,/,
1987/CD
)/)
./.
====================
However/RB
,/,
knowledge/NN
of/IN
the/DT
host/NN
genetic/JJ
factors/NNS
involved/VBN
in/IN
the/DT
progress/NN
of/IN
HBV/NN
infection/NN
and/CC
HCC/NN
occurrence/NN
is/VBZ
insufficient/JJ
now/RB
./.
====================
CYP2E1/NN
,/,
an/DT
ethanol/NN
inducible/JJ
enzyme/NN
,/,
is/VBZ
one/CD
of/IN
the/DT
candidate/NN
genes/NNS
that/WDT
might/MD
influence/VB
the/DT
outcome/NN
of/IN
chronic/JJ
liver/NN
disease/NN
./.
====================
Moreover/RB
,/,
acetaldehyde/NN
,/,
a/DT
highly/RB
toxic/JJ
and/CC
volatile/NN
compound/NN
is/VBZ
the/DT
first/JJ
intermediate/JJ
of/IN
alcohol/NN
metabolism/NN
by/IN
CYP2E1/NN
(/(
Peters/NNS
&/CC
Ward/NN
,/,
1988/CD
)/)
./.
====================
Therefore/RB
,/,
the/DT
level/NN
of/IN
CYP2E1/NN
might/MD
increase/VB
cancer/NN
risk/NN
./.
====================
Many/JJ
researches/VBZ
have/VBP
been/VBN
focused/VBN
on/IN
polymorphisms/NNS
of/IN
the/DT
CYP2E1/NN
./.
====================
There/EX
are/VBP
many/JJ
known/JJ
polymorphic/JJ
loci/NNS
in/IN
the/DT
CYP2E1/NN
./.
====================
Among/IN
these/DT
polymorphisms/NNS
,/,
RsaI/NNP
polymorphism/NN
(/(
CYP2E1*5B/NN
)/)
(/(
rs2031920/CD
)/)
has/VBZ
been/VBN
associated/VBN
with/IN
higher/JJR
transcription/NN
and/CC
increased/VBD
enzyme/NN
activity/NN
and/CC
is/VBZ
located/JJ
at/IN
5/CD
’/NN
regulatory/JJ
region/NN
(/(
Grove/NN
et/FW
al./FW
,/,
1998/CD
;/:
Hayashi/NNP
et/FW
al./FW
,/,
1991/CD
;/:
Tsutsumi/NNP
et/FW
al./FW
,/,
1994/CD
)/)
./.
====================
RsaI/NN
polymorphism/NN
is/VBZ
associated/VBN
with/IN
alcoholic/JJ
liver/NN
disease/NN
in/IN
Asian/JJ
population/NN
(/(
Piao/NN
et/FW
al./FW
,/,
2003/CD
;/:
Tanaka/NNP
et/FW
al./FW
,/,
1997/CD
;/:
Tsutsumi/NNP
et/FW
al./FW
,/,
1994/CD
)/)
./.
====================
Likewise/RB
,/,
some/DT
studies/NNS
show/VBP
that/IN
CYP2E1/NN
polymorphism/NN
were/VBD
associated/VBN
with/IN
risk/NN
of/IN
HCC/NN
(/(
Ladero/NN
et/FW
al./FW
,/,
1996/CD
;/:
Yu/NNP
et/FW
al./FW
,/,
1995/CD
)/)
./.
====================
These/DT
studies/NNS
further/RB
supports/VBZ
the/DT
polymorphism/NN
of/IN
CYP2E1/NN
can/MD
influence/VB
to/TO
risk/NN
of/IN
HCC/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
hypothesized/VBD
that/IN
polymorphisms/NNS
of/IN
CYP2E1/NN
can/MD
affect/VB
HCC/NN
Risk/NN
in/IN
HBV/NN
patient/NN
./.
====================
We/PRP
analyzed/VBD
five/CD
polymorphisms/NNS
of/IN
CYP2E1/NN
via/IN
genotyping/VBG
a/DT
total/JJ
of/IN
1,092/NN
samples/NNS
,/,
including/VBG
658/CD
chronic/JJ
carrier/NN
and/CC
434/CD
spontaneously/RB
recovered/VBD
individuals/NNS
./.
====================
However/RB
,/,
our/PRP$
research/NN
revealed/VBD
that/IN
the/DT
five/CD
polymorphisms/NNS
and/CC
haplotypes/NNS
in/IN
CYP2E1/NN
are/VBP
not/RB
associated/VBN
with/IN
HBV/NN
clearance/NN
,/,
HCC/NN
occurrence/NN
and/CC
onset/NN
age/NN
of/IN
HCC/NN
in/IN
a/DT
Korean/JJ
population/NN
./.
====================
Some/DT
of/IN
the/DT
previous/JJ
studies/NNS
have/VBP
shown/VBN
findings/NNS
on/IN
CYP2E1/NN
polymorphism/NN
associations/NNS
with/IN
CYP2E1/NN
activities/NNS
and/CC
HCC/NN
risk/NN
(/(
Hayashi/NNP
et/FW
al./FW
,/,
1991/CD
;/:
Ladero/NNP
et/FW
al./FW
,/,
1996/CD
;/:
Lucas/NNP
et/FW
al./FW
,/,
1995/CD
;/:
Marchand/CC
et/FW
al./FW
,/,
1999/CD
;/:
Watanabe/NNP
et/FW
al./FW
,/,
1994/CD
;/:
Yu/NNP
et/FW
al./FW
,/,
1995/CD
)/)
./.
====================
However/RB
,/,
other/JJ
previous/JJ
studies/NNS
have/VBP
reported/VBN
that/IN
there/EX
was/VBD
no/DT
association/NN
between/IN
CYP2E1/NN
genetic/JJ
polymorphisms/NNS
and/CC
CYP2E1/NN
activities/NNS
(/(
Carriere/NN
et/FW
al./FW
,/,
1996/CD
;/:
Inoue/NNP
et/FW
al./FW
,/,
2000/CD
;/:
Powell/NN
et/FW
al./FW
,/,
1998/CD
)/)
./.
====================
In/IN
other/JJ
words/NNS
,/,
including/VBG
the/DT
findings/NNS
of/IN
this/DT
study/NN
,/,
the/DT
literature/NN
have/VBP
shown/VBN
contradictory/JJ
findings/NNS
on/IN
associations/NNS
of/IN
CYP2E1/NN
polymorphisms/NNS
with/IN
CYP2E1/NN
activities/NNS
and/CC
HCC/NN
risk/NN
,/,
especially/RB
rs3813867/RB
polymorphism/NN
which/WDT
is/VBZ
in/IN
absolute/JJ
linkage/NN
disequilibrium/NN
(/(
LD/NN
)/)
(/(
|D/NNP
’/RB
|=1/NNP
and/CC
r2=1/RB
)/)
with/IN
RsaI/NNP
polymorphism/NN
(/(
CYP2E1*5B/NN
)/)
(/(
rs2031920/RB
)/)
,/,
which/WDT
is/VBZ
associated/VBN
with/IN
higher/JJR
transcription/NN
,/,
increased/VBD
enzyme/NN
activity/NN
,/,
and/CC
alcoholic/JJ
liver/RB
disease/NN
(/(
Grove/NNP
et/FW
al./FW
,/,
1998/CD
;/:
Hayashi/NNP
et/FW
al./FW
,/,
1991/CD
;/:
Piao/RB
et/FW
al./FW
,/,
2003/CD
;/:
Tanaka/NNP
et/FW
al./FW
,/,
1997/CD
;/:
Tsutsumi/NNP
et/FW
al./FW
,/,
1994/CD
)/)
./.
====================
When/WRB
comparing/VBG
the/DT
contrasting/VBG
results/NNS
of/IN
previous/JJ
researches/NNS
,/,
we/PRP
can/MD
find/VB
different/JJ
statistical/JJ
methods/NNS
and/CC
patient/NN
group/NN
in/IN
the/DT
researches/NNS
./.
====================
Positive/JJ
result/NN
studies/NNS
used/VBD
a/DT
method/NN
of/IN
classification/NN
by/IN
physiological/JJ
determinants/NNS
,/,
especially/RB
drinking/VBG
and/CC
smoking/NN
habits/VBZ
./.
====================
However/RB
,/,
negative/JJ
result/NN
studies/NNS
only/RB
performed/VBN
a/DT
casecontrol/JJ
analysis/NN
without/IN
classifying/VBG
according/VBG
to/TO
alcohol/NN
consumption/NN
./.
====================
Moreover/RB
,/,
a/DT
previous/JJ
study/NN
has/VBZ
shown/VBN
that/IN
the/DT
activity/NN
of/IN
CYP2E1/NN
is/VBZ
modulated/VBN
by/IN
various/JJ
physiological/JJ
determinants/NNS
,/,
such/JJ
as/IN
obesity/RB
(/(
O'Shea/NNP
et/FW
al./FW
,/,
1994/CD
)/)
,/,
fasting/VBG
(/(
O'Shea/NNP
et/FW
al./FW
,/,
1994/CD
)/)
,/,
and/CC
liver/NN
dysfunction/NN
(/(
Dilger/NNP
et/FW
al./FW
,/,
1997/CD
)/)
,/,
and/CC
can/MD
be/VB
induced/VBN
by/IN
ethanol/NN
(/(
Girre/NNP
et/FW
al./FW
,/,
1994/CD
)/)
./.
====================
In/IN
contrast/NN
,/,
dietary/JJ
isothiocyanates/NNS
(/(
Leclercq/NNP
et/FW
al./FW
,/,
1998/CD
)/)
,/,
and/CC
garlic/JJ
(/(
Reicks/NNS
and/CC
Crankshaw/NN
,/,
1996/CD
;/:
Yang/NNP
et/FW
al./FW
,/,
1994/CD
)/)
,/,
as/IN
well/RB
as/IN
some/DT
drugs/NNS
,/,
such/JJ
as/IN
disulfiram/JJ
(/(
Kharasch/NNP
et/FW
al./FW
,/,
1993/CD
)/)
,/,
and/CC
chlormethiazole/NN
(/(
Gebhardt/NNP
et/FW
al./FW
,/,
1997/CD
)/)
,/,
inhibit/VBP
CYP2E1/NN
activity/NN
./.
====================
Therefore/RB
,/,
we/PRP
can/MD
estimate/VB
that/DT
RsaI/NN
polymorphism/NN
is/VBZ
not/RB
associated/VBN
with/IN
CYP2E1/NN
activity/NN
,/,
but/CC
rather/RB
,/,
is/VBZ
associated/VBN
with/IN
inducement/JJ
of/IN
CYP2E1/NN
activity/NN
by/IN
geneenvironment/JJ
interactions/NNS
,/,
including/VBG
links/NNS
with/IN
ethanol/NN
consumption/NN
./.
====================
Moreover/RB
,/,
the/DT
increase/NN
of/IN
CYP2E1/NN
activity/NN
may/MD
be/VB
associated/VBN
with/IN
increase/NN
of/IN
alcoholic/JJ
liver/NN
dis/VBZ
ease/JJ
risk/NN
resulting/VBG
in/IN
increased/VBN
formation/NN
of/IN
ROS/NN
(/(
Hayashi/NNP
et/FW
al./FW
,/,
1991/CD
;/:
Tsutsumi/NNP
et/FW
al./FW
,/,
1994/CD
)/)
./.
====================
This/DT
means/NNS
that/DT
the/DT
findings/NNS
from/IN
previous/JJ
studies/NNS
,/,
which/WDT
suggested/VBD
that/IN
variation/NN
of/IN
CYP2E1/NN
can/MD
influence/VB
the/DT
risk/NN
of/IN
HCC/NN
,/,
is/VBZ
due/JJ
to/TO
CYP2E1/NN
activity/NN
change/NN
by/IN
ethanol/NN
consumption/NN
./.
====================
In/IN
other/JJ
words/NNS
,/,
we/PRP
can/MD
presume/VB
that/DT
if/IN
the/DT
influence/NN
of/IN
environmental/JJ
factors/NNS
would/MD
have/VBP
been/VBN
be/VB
same/JJ
,/,
then/RB
there/EX
would/MD
be/VB
no/DT
association/NN
signals/NNS
for/IN
the/DT
polymorphisms/NNS
./.
====================
We/PRP
can/MD
presumption/NN
that/DT
CYP2E1/NN
polymorphism/NN
is/VBZ
associated/VBN
with/IN
CYP2E1/NN
activity/NN
induced/VBN
by/IN
ethanol/NN
,/,
but/CC
is/VBZ
not/RB
directly/RB
associated/VBN
with/IN
HCC/NN
risk/NN
./.
====================
However/RB
,/,
we/PRP
can/MD
estimate/VB
another/DT
hypothesissuggesting/JJ
that/DT
this/DT
contradictory/JJ
result/NN
may/MD
be/VB
affected/VBN
by/IN
racial/JJ
differences/NNS
./.
====================
Additional/JJ
studies/NNS
are/VBP
needed/VBN
to/TO
clarify/VB
the/DT
association/NN
of/IN
CYP2E1/NN
with/IN
HCC/NN
risk/NN
in/IN
other/JJ
ethnic/JJ
populations/NNS
./.
====================
In/IN
conclusion/NN
,/,
this/DT
study/NN
presents/VBZ
that/DT
even/RB
if/IN
CYP2E1/NN
may/MD
have/VB
important/JJ
functions/NNS
in/IN
the/DT
HBV/NN
clearance/NN
and/or/CC
HCC/NN
occurrence/NN
,/,
genetic/JJ
variants/NNS
of/IN
CYP2E1/NN
in/IN
this/DT
study/NN
probably/RB
do/VBP
not/RB
influence/VB
HBV/NN
clearance/NN
and/or/CC
HCC/NN
occurrence/NN
./.
====================
Although/IN
we/PRP
could/MD
not/RB
find/VB
any/DT
significant/JJ
associations/NNS
,/,
the/DT
information/NN
from/IN
this/DT
research/NN
would/MD
be/VB
useful/JJ
for/IN
host/NN
genetic/JJ
studies/NNS
of/IN
CYP2E1/NN
related/JJ
diseases/NNS
,/,
including/VBG
HCC/NN
./.
====================
Moreover/RB
,/,
CYP2E1/NN
novel/JJ
polymorphisms/NNS
,/,
which/WDT
were/VBD
identified/VBN
in/IN
our/PRP$
research/NN
,/,
will/MD
be/VB
useful/JJ
for/IN
studies/NNS
on/IN
alcohol/NN
related/JJ
diseases/NNS
./.
====================
